Prévisions
L'objectif de cours moyen des analystes est de 910,05 € (-6,67 %). La médiane est de 911,35 € (-6,54 %).
| Acheter |
25 |
| Conserver |
6 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Alluvium raises McKesson stake after management reiterates 13–16% long‑term growth target
Alluvium Asset Management said it increased its position in McKesson after the drug distributor reported full‑year results in line with expectations and management reaffirmed 13–16% long‑term earnings growth. The fund’s valuation model rose about 18% versus the share price, leading McKesson to represent 6.8% of the Conventum – Alluvium Global Fund. McKesson closed at $899.56 on September 15, with a 52‑week gain near 30% and recent analyst commentary describing its FY27 outlook as "good enough." » Plus sur finance.yahoo.com
McKesson raises full-year outlook after oncology expansion
At the Morgan Stanley Healthcare Conference, McKesson raised its EPS outlook for 2027 to $44.20–45.00 and sees reported growth of 13–15%. Strong results in the Oncology and Multispecialty segment and expansion in oncology and biopharma services—including the planned acquisition of Precision Medicine Group—are driving the improvement. The med-surg business is under pressure, while buybacks, higher dividends and a planned spinoff of Wellverse support capital allocation and shareholder returns. » Plus sur de.investing.com
McKesson to buy Precision Medicine Group for $2.25 billion as oncology growth accelerates
McKesson plans to acquire Precision Medicine Group for $2.25 billion to add oncology-focused CRO, clinical-trial and market-access capabilities to its Oncology and Multi-Specialty segment, subject to regulatory approval. The company reported strong first-quarter results, with North American Pharmaceutical Distribution revenue up ~5% and Oncology and Multi-Specialty revenue and profit rising about 33% and 41%, respectively. McKesson expects to return roughly $5 billion to shareholders this year, including $2.5 billion in buybacks and a 15% dividend increase, while continuing investments in automation, AI and other growth initiatives. The firm is also progressing with the separation of its Medical-Surgical business, rebranded as Wellverse, targeted for the back half of next year. » Plus sur finance.yahoo.com
McKesson buys Precision Medicine Group for $2.25 billion to boost oncology
McKesson will acquire Precision Medicine Group for about $2.25 billion to expand its Oncology & Multispecialty business with clinical research, lab testing and commercialization services. The deal aligns with McKesson's strategy of exiting non-core assets and investing in higher-growth specialty and oncology areas. Management expects the acquisition to strengthen clinical trial execution and biopharma offerings, but no closing timeline was provided and integration, scalability and near-term earnings impact remain uncertain. » Plus sur finance.yahoo.com
McKesson buys Precision Medicine Group for $2.25 billion, strengthens oncology segment
McKesson has signed a definitive agreement to acquire Precision Medicine Group for about $2.25 billion, a move investors view as expanding its oncology and multispecialty strategy. Precision Medicine Group provides clinical research services, biomarker analysis, laboratory services and commercialization support for biotech and pharma companies. The acquisition follows a restructuring that refocused McKesson on higher-margin, faster-growing areas; its oncology and multispecialty business recently grew by 33%. analyst backing and a dividend increase have supported the positive market reaction; the stock rose sharply intraday and is approaching its 52-week high. » Plus sur de.investing.com
Dividendes historiques Dividendes
Tous les indicateurs de dividendes Tous les indicateursEn 2026, McKesson a déjà versé 2,97 € de dividendes. Le dernier versement a eu lieu en octobre.
Données financières
Au dernier trimestre, McKesson a réalisé un chiffre d'affaires de 97,96 Md € et un bénéfice net de 1,08 Md €
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 97,96 Md | 11,45 % |
| Bénéfice brut | 3,49 Md | 15,71 % |
| Bénéfice net | 1,08 Md | 13,69 % |
| EBITDA | 1,65 Md | 16,55 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 111,76 Md € |
Nombre d'actions | 115,46 M |
Plus haut/bas sur 52 semaines | 1 022,08 € - 659,53 € |
Rendement du dividende | 0,30 % |
Dividendes TTM | 2,96 € |
Bêta | 0,28 |
Ratio P/E | 27,20 |
Ratio PEG | 1,29 |
Ratio P/B | -31,24 |
Ratio P/S | 0,29 |
Profil de l'entreprise
McKesson Corporation fournit des services de santé aux États-Unis et à l'international. Elle exerce ses activités à travers quatre segments : U.S. Pharmaceutical, International, Medical-Surgical Solutions et Prescription Technology Solutions (RxTS). Le segment U.S. Pharmaceutical distribue des médicaments de marque, génériques, de spécialité, biosimilaires et en vente libre, ainsi que d'autres produits liés à la santé. Ce segment fournit également des services de gestion de cabinet, de technologie, de soutien clinique et de solutions commerciales aux cabinets d'oncologie et autres cabinets de spécialité de proximité, ainsi que des services de conseil, d'externalisation, technologiques et autres, et vend des solutions financières, opérationnelles et cliniques aux pharmacies. Le segment International propose des services de distribution aux clients grossistes, institutionnels et de détail dans 13 pays européens et au Canada. Le segment Medical-Surgical Solutions assure la distribution de fournitures médico-chirurgicales, la logistique et d'autres services aux prestataires de soins de santé. Le segment RxTS s'adresse aux partenaires des biopharmaceutiques et des sciences de la vie ainsi qu'aux patients, afin de répondre aux difficultés liées aux médicaments tout au long du parcours des patients ; il met en relation pharmacies, prestataires de soins, payeurs et entreprises biopharmaceutiques pour proposer des solutions innovantes d'accès et d'observance ; et fournit des solutions logistiques externalisées (tierce partie) et de soutien à la distribution en gros. McKesson Corporation a été fondée en 1833 et son siège social se situe à Irving, au Texas.
| Nom | McKesson |
| PDG | Brian S. Tyler |
| Siège social | Irving,
tx États-Unis |
| Site web | |
| Secteur | Santé |
| Industrie | Prestataires et services de santé |
| Introduction en bourse | 10/11/1994 |
| Employés | 42 300 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NYSE | MCK |
London Stock Exchange | 0JZU.L |
Frankfurt | MCK.F |
Düsseldorf | MCK.DU |
London | 0JZU.L |
SIX | MCK.SW |
München | MCK.MU |